2Ghobrial IM.Myeloma as a model for the process of metasta-sis:implications for therapy[].Blood.2012
3ROSINOL L,CIBEIRA MT,BLADE J,et al.Extramedullary multiple myeloma escapes the effect of thalidomide[].Haemato-logica.2004
4M Varettoni,A Corso,G Pica,S Mangiacavalli,C Pascutto,M Lazzarino.Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients[].Annals of Oncology.2009
5Huang S,Yao M,Tang J-L,et al.Epidemiology of multiple myeloma in Taiwan[].Cancer.2007
6Jose M,Calvo-Villas,Adrian Alegre,Carmen Calle,Miguel T.Lenalido-mide is effective for extramedullary disease in relapsed or refractory multiple myeloma[].European Journal of Haematology.2011
二级参考文献7
1Jennings CD, Foon KA. Recent advances in flow cytometry: application to the diagnosis of hematologic malignancy. Blood, 1997; 90:2863 - 2892
2Harada H, Kawano MM, Huang N, et al. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood, 1993; 81:2658 - 2663
3Van-Camp B, Durie BG, Spier C, et al. Plasma cells in multiple myaloma express a natural killer cell-associated antigen: CD56(NKH-1; Leu-19). Blood, 1990; 76:377- 382
4Gonzalez M, San Miguel JF, Gascon A, et al. Increased expression of natural-killer-associated and activation antigens in multiple myeloma. Am J Hematol, 1992; 39:84- 89
5Lapena P, Prieto A, Garcia-Suarez J, et al. Increased expression of CD56 and HLA/DR antigens in CD2 + cells from multiple myeloma patients. Am J Hematol, 1994; 46:158- 159
6Kawano MM, Huang N, Tanaka H, et al. Homotypic cell aggregations of human myeloma cells with ICAM-1 and LFA-1 molecules.Br J Haematol, 1991; 79:583 - 588
7Menke DM, Horny HP, Griesser H, et al. Immunophenotypic and genotylic characterisation of multiple myelomas with adverse prognosis characterised by immunohistological expression of the T cell related antigen CD45RO(UCHL-1). J Clin Pathol, 1998; 51..432 - 437
